Alto Neuroscience (ANRO)

Executive Summary

Alto Neuroscience is a clinical-stage biopharmaceutical company leveraging AI and machine learning to develop precision therapies for neuropsychiatric disorders. Its pipeline includes ALTO-100 (a potential cognitive enhancer for major depressive disorder and bipolar depression), ALTO-300 (a novel antidepressant targeting circadian rhythm), and ALTO-203 (a selective antagonist for anhedonia). The company's approach uses biomarker-driven patient selection to increase trial success rates. With multiple Phase 2 trials underway or recently completed, Alto is positioned to deliver key data readouts in the next 12-18 months. If successful, these results could validate its precision psychiatry platform and lead to pivotal trials, offering a personalized medicine approach in a large unmet need area. However, the company faces execution risk and competition from other CNS-focused biotechs.

Upcoming Catalysts (preview)

• Q4 2026ALTO-300 Phase 2 Top-Line Data in Major Depressive Disorder50% success
• Q3 2026ALTO-100 Phase 2 Data in Bipolar Depression45% success
• Q3 2026Biomarker Validation Update from Ongoing Studies60% success